🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Kapiva spends Rs 188 Cr on advertising in FY25; posts Rs 342 Cr revenue

EntrackrEntrackr · 2m ago
Kapiva spends Rs 188 Cr on advertising in FY25; posts Rs 342 Cr revenue
Medial

Kapiva sustained its strong growth momentum in the fiscal year ended March 31, 2025, as revenue rose nearly 50% year on year. However, higher incremental spending during the year weighed on the bottom line and led to a 23% increase in the company’s losses over the same period. Kapiva’s revenue from operations grew 50% to Rs 342 crore in FY25 from Rs 228 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). Founded in 2015, Kapiva is an ayurvedic nutrition brand offering natural and organic products in categories such as diabetes, hypertension, liver health, hormonal balance, wellness, energy, and sports nutrition. Sale of these products was the sole source of revenue for the company. Including non-operating income of Rs 7 crore, the company’s total income stood at Rs 349 crore in FY25. For the D2C brand, advertising and promotional expenditure remained the largest cost contributor, accounting for 45% of the total expense. This cost rose 53% to Rs 188 crore in FY25 from Rs 123 crore in FY24. Cost of materials consumed grew 43% to Rs 97 crore, contributing about 23% of overall costs, while employee benefit expenses increased 28% to Rs 59 crore. Transportation cost stood at Rs 22 crore, legal charges doubled to Rs 16 crore, and other overheads added another Rs 36 crore during the year. Overall, the company’s total expense rose 44% to Rs 418 crore in FY25 from Rs 290 crore in FY24. Kapiva’s net loss rose 23% to Rs 69 crore in FY25 from Rs 56 crore in FY24. Its ROCE and EBITDA margin stood at -51.41% and -20.88% respectively. On a unit level, the company spent Rs 1.22 to earn a rupee, better than Rs 1.27 it spent in FY24. The company recorded cash and bank balances of Rs 139 crore, while its current assets were valued at Rs 199 crore in the same period.

ZeroHarm Sciences raises Rs 65 Cr in Series A round

EntrackrEntrackr · 14d ago
ZeroHarm Sciences raises Rs 65 Cr in Series A round
Medial

ZeroHarm Sciences raises Rs 65 Cr in Series A round Nano formulated plant based nutraceutical brand ZeroHarm Sciences has raised Rs 65 crore ($7.15 million) in a Series A funding round. Kotak Alternate Asset Managers Limited, through its Kotak Life Sciences Fund I, invested Rs 40 crore, while Alkemi Growth Capital invested Rs 25 crore. The funds will be used for national brand building, international expansion across the USA, the UK, and the Middle East, and scaling research and manufacturing capabilities, the company said in a press release. Founded in 2020 by Sachin and Shweta Darbarwar, ZeroHarm Sciences develops plant based health supplements using proprietary nano formulation technology. The company aims to build India’s first Trust over Promise health platform, where supplement efficacy is demonstrated through measurable consumer health outcomes. The Hyderabad based company converts plant based nutrients into nano sized particles to improve bioavailability and enable controlled release at lower dosages. It integrates ayurveda with advanced technology to deliver preventive wellness solutions. ZeroHarm controls the value chain from medicinal plant sourcing through a network of over 10000 farmers in Northeast India and the Himalayas. The company has filed and received patents for nano formulations covering turmeric based phytochemicals, iron folic acid combinations, carotenoid based eye health, and synbiotic gut health compositions. The company offers over 60 SKUs across categories such as diabetes management, heart health, joint care, immunity, gut health, oncology support, women’s wellness, and performance nutrition. Products are sold through its website, Amazon, Flipkart, and quick commerce platforms, and the brand has served more than 300000 customers. India’s nutraceutical market is projected to reach $18 billion by 2025, while the global market is expected to cross $720 billion by 2027. ZeroHarm competes with players including Kapiva, Plix, HealthKart, and Wellbeing Nutrition.

Marico acquires 60% stake in D2C nutrition startup Cosmix

EntrackrEntrackr · 1m ago
Marico acquires 60% stake in D2C nutrition startup Cosmix
Medial

Marico acquires 60% stake in D2C nutrition startup Cosmix Mumbai-based multinational consumer goods company Marico has acquired a 60% majority stake in Cosmix, a startup that sells plant-based protein supplements, at an equity valuation of Rs 375 crore. With this deal, Marico expands its D2C presence by adding another brand. The acquisition brings a protein-focused brand into Marico’s D2C portfolio. Founded in 2019, Cosmix operates as a digital-first nutrition brand with a focus on plant-based protein and wellness products. The startup sells primarily through its own website and online marketplaces. Cosmix has remained profitable since inception and reported revenue of around Rs 50 crore in FY25, compared to Rs 24 crore in FY24. According to the company, it has scaled to an ARR of Rs 100 crore. Marico has been actively acquiring and scaling D2C brands over the past few years. In 2017, it acquired men’s grooming brand Beardo. As per TheKredible, Beardo’s revenue crossed Rs 200 crore in FY25, while its profit increased 3.6 times on a year-on-year basis. Apart from Beardo, Marico’s D2C portfolio includes brands such as Plix, True Elements, and Just Herbs. The development follows a similar move in the FMCG sector, where Hindustan Unilever Limited (HUL) acquired homegrown skincare brand Minimalist last year at a pre-money valuation of Rs 2,955 crore.

Download the medial app to read full posts, comements and news.